All supplements

Supplement evidence

094 / 575Cognition

Ginkgo biloba

View my plan

The short answer

Standardized extracts have mixed evidence for dementia symptoms and do not prevent dementia in healthy adults.

Evidence and scope
Mixed evidence

This status does not grade the ingredient for every goal, outcome, or person.

Important limitation
Trials are inconsistent or small, so a reliable clinically important benefit is not established.
Before deciding
Key concern: Anticoagulants, antiplatelets, seizures, diabetes medicines, surgery, and raw seeds are major concerns.

01 / PRACTICAL GUIDE

Dose, absorption, and combinations

These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.

Reference range by objective
Cognitive-performance research120–240 mg/day standardized extract in trials

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source

More is not automatically better. A clinician or product label may specify a different amount.

Absorption / solubilityFormulation-dependent

Not usefully classified as a fat- or water-soluble vitamin; absorption depends on the salt, extract, delivery system, and meal.

How it is commonly taken

Divide with meals; use only standardized leaf extract.

Do not combine casually

Anticoagulants, antiplatelets, seizures, diabetes medicines, surgery, and raw seeds are major concerns.

Dose and use source

Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.

02 / EVIDENCE

What the research says

We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.

1research papers in this ledger
82unique primary studies represented
10,613unique participants represented

These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.

Open the research timelineResearch timeline

Entries are ordered by publication year. A study period appears only when the source reports it.

2026
Mixed or qualifiedPMID 41641880 · CD013661

Ginkgo biloba for cognitive impairment and dementia

Moderate-certainty evidence found little or no six-month benefit in mild cognitive impairment. Low-certainty evidence suggested small-to-moderate six-month benefits in dementia, with very high heterogeneity; results do not show prevention or slowed progression and should not replace dementia evaluation or care.

Study design and methods
Design
Cochrane systematic review of 82 randomized trials
Population
10,613 people with subjective cognitive complaints, mild cognitive impairment, multiple sclerosis with cognitive problems, or dementia
Intervention
Ginkgo preparations versus placebo, usual care, or other treatments
Outcome
Global clinical status, cognition, activities of daily living, adverse events, and serious adverse events

Funding or conflict note: Review authors reported no commercial ginkgo conflicts; several held Cochrane roles but were excluded from the editorial process.

Open research record
Unscreened discovery appendix—not evidence91 candidate publicationsSearch run: Aug 21, 2026

Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.

03 / SOURCES

Start with the source material

The live search is for discovery only. Search-result counts change and are not included in the audited totals above.

Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.
  1. Ginkgo biloba for cognitive impairment and dementia.Wieland LS, Ludeman E, Chi Y et al. · 2026 · The Cochrane database of systematic reviews · PMID 41641880Open on PubMed
  2. Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trials.Riepe M, Hoerr R, Schlaefke S · 2025 · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · PMID 39895346Open on PubMed
  3. Effect of long-term pharmacological treatments on Alzheimer disease: A systematic review and network meta-analysis.Deng X, Li D · 2024 · Medicine · PMID 39312316Open on PubMed
  4. Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized controlled and open-label observation trial.Lee W, Kim M · 2024 · Medicine · PMID 38875437Open on PubMed
  5. Efficacy of ginkgo diterpene lactone meglumine on cognitive function in patients with acute ischemic stroke: a predefined exploratory analysis of a multicenter, double-blind, randomized controlled trial.Tian X, Xu Q, Xia X et al. · 2024 · Journal of neurology · PMID 38472398Open on PubMed
  6. Clinical effectiveness of pharmacological and non-pharmacological treatments for the management of anxiety in community dwelling people living with dementia: A systematic review and meta-analysis.Nimmons D, Aker N, Burnand A et al. · 2024 · Neuroscience and biobehavioral reviews · PMID 38097097Open on PubMed
  7. A systematic review of the safety and efficacy on cognitive function of herbal and nutritional medicines in older adults with and without subjective cognitive impairment.Cave AE, Chang DH, Münch GW et al. · 2023 · Systematic reviews · PMID 37592293Open on PubMed
  8. Efficacy and safety of herbal medicine on dementia and cognitive function: An umbrella review of systematic reviews and meta-analysis.Sawangjit R, Chuenchom C, Sanverm T et al. · 2023 · Phytotherapy research : PTR · PMID 36728740Open on PubMed
  9. A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress.Morató X, Marquié M, Tartari JP et al. · 2023 · Scientific reports · PMID 37012306Open on PubMed
  10. EGb in the Treatment for Patients with VCI: A Systematic Review and Meta-Analysis.Zhan M, Sun L, Liu J et al. · 2021 · Oxidative medicine and cellular longevity · PMID 34504643Open on PubMed
  11. Meta-analysis of Ginkgo biloba Preparation for the Treatment of Alzheimer's Disease.Liao Z, Cheng L, Li X et al. · 2020 · Clinical neuropharmacology · PMID 32658034Open on PubMed
  12. Effect of Pushen capsule for treating vascular mild cognitive impairment: a pilot observational study.Li S, Cao G, Deng Q et al. · 2019 · The Journal of international medical research · PMID 31407622Open on PubMed

04 / EXPERT CONTEXT

Expert context—not evidence

Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.

No direct, source-verified endorsement is currently recorded. Research authorship or discussion alone is not treated as endorsement.

Educational information only—not medical advice. Product quality, dose, medicines, pregnancy, and kidney or liver disease can materially change safety.